InvestSMART

ReNerve Limited (ASX: RNV) - Share Price

- Current share price for RNV : $0.070

ReNerve Limited (RNV) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is an Australian biotechnology company that has altered peripheral nerve surgery with its ready-to-use solutions for peripheral nerve injuries (PNI).

RNV General Information +

ASX Code RNV
Website http://www.renerve.com.au
Industry/Sector Health Care Supplies
Market Cap ($M) 9
RNV Share Price $0.070
Day High $0.070
Day Low $0.070
Last Close $0.070
RNV Share Price Movement - ( No change )
Prices as at 16:40, 20 Nov 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

ReNerve Limited (RNV) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from ReNerve Limited (RNV) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

ReNerve Limited (RNV) price-sensitive announcements

RNV - Release of Securities from Escrow
ReNerve Limited announced under ASX Listing Rule 3.10A that 39,935,726 fully paid ordinary
ReNerve Limited (RNV)
19 Nov 2026 | 10:42 AM
RNV - First patient in India receives NervAlign Nerve Cuff
ReNerve Limited announced that the first patient in India has been treated with its FDA-cl
ReNerve Limited (RNV)
17 Nov 2026 | 9:18 AM
RNV - Q1 FY27 Activities Report and Appendix 4C
ReNerve Limited’s Q1 FY27 Activities Report and Appendix 4C for the quarter ended 30 Septe
ReNerve Limited (RNV)
26 Oct 2026 | 9:52 AM
RNV - Positive 12-Month Data for NervAlign Nerve Guide Matrix
ReNerve Limited announced positive interim 12-month preclinical results for its NervAlign®
ReNerve Limited (RNV)
19 Oct 2026 | 9:20 AM

ReNerve Limited (RNV) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
ReNerve Limited (RNV)
ORDINARY FULLY PAID
Health Care $10 Release of Securities from Escrow 19 Nov 2026 10:42AM $0.080 $0.070 fallen by 12.50%
ReNerve Limited (RNV)
ORDINARY FULLY PAID
Health Care $10 First patient in India receives NervAlign Nerve Cuff 17 Nov 2026 9:18AM $0.084 $0.070 fallen by 16.67%
ReNerve Limited (RNV)
ORDINARY FULLY PAID
Health Care $10 Quarterly Investor Presentation 2 Nov 2026 10:36AM $0.090 $0.070 fallen by 22.22%
ReNerve Limited (RNV)
ORDINARY FULLY PAID
Health Care $10 Becoming a substantial holder 28 Oct 2026 3:58PM $0.090 $0.070 fallen by 22.22%
ReNerve Limited (RNV)
ORDINARY FULLY PAID
Health Care $10 Notification regarding unquoted securities - RNV 28 Oct 2026 1:56PM $0.092 $0.070 fallen by 23.91%
ReNerve Limited (RNV)
ORDINARY FULLY PAID
Health Care $10 Quarterly Report Webinar 26 Oct 2026 9:53AM $0.087 $0.070 fallen by 19.54%

RNV Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2026A -$5.57 -$3.50 15.50% 0.00 0.00 0.00% 0.0%
2025A -$3.73 -$3.00 44.30% 0.00 0.00 0.00% 0.0%
2024A -$2.98 -$2.10 65.40% 0.00 0.00 0.00% 0.0%

RNV Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2024 A 2025 A 2026 A 2024 A 2025 A 2026 A 2024 A 2025 A 2026 A
Ansell Limited (ANN) $6,467M 0.1231 -0.0752 0.1003 21.4492 23.1934 21.0794 2.15% 1.81% 2.01%
Nanosonics Limited (NAN) $895M -0.1375 -0.3934 0.8571 51.8198 85.4286 46.0000 0.00% 0.00% 0.00%
Polynovo Limited (PNV) $577M -0.0899 -0.4186 1.0000 48.5465 83.5000 41.7500 0.00% 0.00% 0.00%
ReNerve Limited (RNV) $10M 0.1551 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%

RNV Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 3.80 0.00
Market 0.27 13.00 1.00 0.72
Sector 0.66 19.70 1.98 2.65

RNV Directors

Name Position Start Date
Dr Julian John Chick Chief Executive Officer, Executive Director 16 Sep 2016
Ms Maja Aleksandra McGuire Interim Chairman, Non-Executive Director 4 Dec 2025
Mr Paul Savage Non-Executive Director 4 Dec 2025

ReNerve Limited (RNV) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
11 Sep 2026 CHICK, Julian Buy Indirect Shares 128,036 $0.075 $9,641.111
31 Jul 2026 CHICK, Julian Buy Direct Shares 292,565 $0.083 $24,341.408
31 Jul 2026 CHICK, Julian Buy Indirect Shares 292,565 $0.083 $24,341.408

See all changes in directors' interest & trades for ReNerve Limited (RNV) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

RNV Management

Name Position
David Lilja Chief Financial Officer,Company Secretary

RNV Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in ReNerve Limited (RNV). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
12,458,090 (7.23%) Ropehawn Investments Pty Ltd
11,527,500 (6.69%) Lucen Pty Ltd
10,170,788 (5.90%) Zetland Road Pty Ltd

RNV Calendar of Events

Date Event
27 August 2027 Report (Annual)
27 August 2027 Report (Prelim)
25 February 2027 Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.